NCT06690775
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 18 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 55 words
- Enrollment closed, study ongoing
- Trial sites expanded: 66 → 81 locations
- Minor Study sites: 56 to 66v17
- Minor Study sites: 53 to 56v16
- Minor Study sites: 42 to 53v15
- Minor Study sites: 40 to 42v14
Show 12 earlier versionsHide 12 earlier versions
- Minor Study sites: 37 to 40v13
- Minor Study sites: 33 to 37v12
- Minor Study sites: 28 to 33v11
- Minor Study sites: 24 to 28v10
- Minor Study sites: 21 to 24v9
- Minor Study sites: 17 to 21v8
- Minor Study sites: 15 to 17v7
- Minor Site details revised at 4 of 15 sitesv6
- Minor Study sites revised (15)v5
- Notable Eligibility criteria revised
- Study sites: 1 to 15
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 1
- Start date changed from estimate of Nov 2024 to Nov 20, 2024
- Minor Study title shortened, about 1 wordv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.
Drugs: TORL-1-23, Pegfilgrastim (drug)
Sites
81 sites in 13 countries
United States 30, Canada 8, South Korea 7, Australia 5, Belgium 4, Czechia 4, Germany 4, Italy 4, Austria 3, France 3, Ireland 3, Singapore 3, Spain 3